

A Joint Royal College of Physicians of Edinburgh and Royal College of Obstetricians and Gynaecologists



Consensus Conference on

ANTI-D PROPHYLAXIS

Tuesday, 8th and Wednesday, 9th April 1997



Queen Mother Conference Centre, Royal College of Physicians,
9 Queen Street, Edinburgh

Prevention of Rh disease has been one of the major success stories of antenatal care – yet there are still problems to solve...


A panel of international experts and speakers will seek a consensus view on areas of controversy in the use of anti-D immunoglobulin under the following headings:-

- current guidelines on anti-D prophylaxis – are they effective; can they be improved?
 - antepartum anti-D prophylaxis – is it worthwhile, and can we afford it?
 - monoclonal anti-D – is it safe, will it work and can it replace polyclonal anti-D?
 - should anti-D be used for treatment of immune thrombocytopenia?
- Ethical considerations and cost effectiveness of anti-D prophylaxis and anti-D provision.

The meeting will be a mixed format with at least one session being "adversarial".

For further details on the conference please contact:


Education, Audit and Research Department,
Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh, EH2 1JQ.
Telephone: (0131) 225 7324 · Facsimile: (0131) 220 4393



ORDER NOW ON OUR CREDIT CARD HOTLINE:

gnancy

ncy." Practice Outlook



Inspired control from their early months

PRESCRIBING INFORMATION

Presentations: Pulmicort Respules. (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1mg twice daily. Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contraindications, warnings, etc.:** Contraindications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care: see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side-effects:** Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a β_2 -agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal status:** POM. **Basic NHS price:** Pulmicort Respules 0.25mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5mg/ml (20 single dose units) £44.64. **Product licence nos.:** Pulmicort Respules 0.25mg/ml PL 0017/0309. Pulmicort Respules 0.5mg/ml PL 0017/0310. **Name and address of Product Licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.



Pulmicort[®]
Respules[®]
BUDESONIDE

Nebulised Steroid Control

ASTRA
Astra Pharmaceuticals

© Registered Trademark
Date of preparation: May 1995
P.Res. 0524